Article
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor…
Read More
– 100% of 9 treated BCCs (1 superficial, 4 nodular, and 4 infiltrating) across 7 enrolled subjects to date demonstrate prompt, visible, and robust tumor responses during treatment with SM-020 1% BID for 28 days, resulting in partial or total reduction of clinically visible tumor. Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–DermBiont, a clinical-stage biotechnology…
Read More
Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients…
Read More
Equity investment reflects commitment to Treg science and support of Abata’s approach and programs Excerpt from the Press Release: WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it has received an equity investment from Bristol Myers…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1…
Read More Excerpt from the Press Release: TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of a…
Read More Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish results today from the COSMOS study confirming the high sensitivity and specificity of the Guardant Reveal blood test in predicting recurrence…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of…
Read More
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Excerpt from the Press Release: Carlsbad, CA, Aug. 08, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI)…
Read More
– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – Excerpt from the Press Release: SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc.…
Read More